Inari Medical plans to buy LimFlow Medical for up to $415M

The LimFlow System for Transcatheter Arterialization of Deep Veins diverts blood from a diseased tibial artery to a tibial vein to deliver oxygen to a patient’s ischemic foot. [Illustration courtesy of LimFlow]Inari Medical (NASDAQ: NARI) + today announced a definitive agreement to purchase LimFlow Medical for up to $415 million.

The deal comes just weeks after Paris-based LimFlow won FDA premarket approval (PMA) for its breakthrough system to treat chronic limb-threatening ischemia (CLTI).

San Jose, California–based Inari said it expects to complete the acquisition by the end of 2023. Inari will pay $250 million in cash at closing, plus up to $165 million based on certain commercial and reimbursement milestones.

Medical Design & Outsourcing: How LimFlow’s foot-saving system prevents amputations in patients with no other options

Inari CEO Drew Hykes said the LimFlow acquisition “is closely aligned …

Read more
  • 0